Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22733566 | 1.00 | TSHR (0.32) | TSHR | |
| SCHEMBL20857233 | 1.00 | TSHR (0.32) | TSHR | |
| SCHEMBL14791314 | 1.00 | TSHR (0.32) | TSHR | |
| SCHEMBL15858403 | 1.00 | TSHR (0.32) | TSHR | |
| SCHEMBL10285141 | 1.00 | TSHR (0.32) | TSHR | |
| SCHEMBL14783023 | 1.00 | TSHR (0.32) | TSHR | |
| SCHEMBL15467069 | 1.00 | TSHR (0.32) | TSHR | |
| SCHEMBL22821367 | 0.87 | MEN1 (0.31) | — | |
| SCHEMBL3805311 | 0.85 | — | — | |
| SCHEMBL23519077 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 788 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130030212-A1 | COMPOUND HAVING ALICYCLIC STRUCTURE, (METH)ACRYLIC ACID ESTER, AND PROCESS FOR PRODUCTION OF THE (METH)ACRYLIC ACID ESTER | IDEMITSU KOSAN CO., LTD. (JP) | 2013-01-31 | — | — | US | claimed |
| EP-1081150-B1 | 4-Oxatricyclo(4.3.1.1-3,8)undecan-5-one derivatives and process for producing the same | DAICEL CHEM (JP) | 2003-10-29 | — | — | EP | claimed |
| US-20030059710-A1 | Monomer having electron-withdrawing group and process for preparing the same | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2003-03-27 | — | — | US | claimed |
| US-6486330-B1 | 4-oxatricyclo[4.3.1.1 3,8]undecan-5-one derivative and process for producing the same | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2002-11-26 | — | — | US | claimed |
| EP-1081150-A1 | 4-Oxatricyclo(4.3.1.1-3,8)undecan-5-one derivatives and process for producing the same | Daicel Chemical Industries, Ltd. (JP) | 2001-03-07 | — | — | EP | claimed |
| US-5430193-A | Synthesis of 4-hydroxy-2-adamantanes and related compounds | MOBIL OIL CORPORATION (US) | 1995-07-04 | — | — | US | claimed |
| US-5298666-A | Synthesis of adamantane-2,4-dione | MOBIL OIL CORPORATION (US) | 1994-03-29 | — | — | US | claimed |
| EP-4703352-A1 | SULFONATE, OXIME SULFONATE, IMIDE SULFONATE, AMIDE SULFONATE, ACID GENERATING AGENT CONTAINING SAID COMPOUND, AND PHOTORESIST CONTAINING SAID ACID GENERATING AGENT | San-Apro Ltd. (JP) | 2026-03-04 | — | — | EP | disclosed |
| US-12545753-B2 | Curable composition | DAICEL CORPORATION (JP) | 2026-02-10 | — | — | US | disclosed |
| US-20260028231-A1 | SURFACE-MODIFIED NANODIAMONDS AND METHOD FOR PRODUCING SURFACE-MODIFIED NANO CARBON PARTICLES | DAICEL CORPORATION (JP) | 2026-01-29 | — | — | US | disclosed |
| US-12534374-B2 | Surface-modified nanodiamond and method for producing surface-modified nanodiamond | DAICEL CORPORATION (JP) | 2026-01-27 | — | — | US | disclosed |
| US-12479731-B2 | Surface-modified nanodiamonds and method for producing surface-modified nano carbon particles | DAICEL CORPORATION (JP) | 2025-11-25 | — | — | US | disclosed |
| US-12460147-B2 | Composition for refrigeration machine and composition kit for refrigeration machine | DAICEL CORPORATION (JP) | 2025-11-04 | — | — | US | disclosed |
| EP-1081150-A1 | 4-Oxatricyclo(4.3.1.1-3,8)undecan-5-one derivatives and process for producing the same | Daicel Chemical Industries, Ltd. (JP) | 2001-03-07 | — | — | EP | disclosed |
| EP-1081150-A1 | 4-Oxatricyclo(4.3.1.1-3,8)undecan-5-one derivatives and process for producing the same | Daicel Chemical Industries, Ltd. (JP) | 2001-03-07 | — | — | EP | disclosed |
| EP-1081150-A1 | 4-Oxatricyclo(4.3.1.1-3,8)undecan-5-one derivatives and process for producing the same | Daicel Chemical Industries, Ltd. (JP) | 2001-03-07 | — | — | EP | disclosed |
| US-5430193-A | Synthesis of 4-hydroxy-2-adamantanes and related compounds | MOBIL OIL CORPORATION (US) | 1995-07-04 | — | — | US | disclosed |
| US-5410092-A | Synthesis of adamantane-2,4-dione | MOBIL OIL CORPORATION (US) | 1995-04-25 | — | — | US | disclosed |
| US-5298666-A | Synthesis of adamantane-2,4-dione | MOBIL OIL CORPORATION (US) | 1994-03-29 | — | — | US | disclosed |
| US-4985403-A | Use of adamantane derivatives in augmenting or enhancing the aroma of consumable materials | INTERNATIONAL FLAVORS & FRAGRANCES INC. (US) | 1991-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130030212-A1 | COMPOUND HAVING ALICYCLIC STRUCTURE, (METH)ACRYLIC ACID ESTER, AND PROCESS FOR PRODUCTION OF THE (METH)ACRYLIC ACID ESTER | ALAD, MMAB, MAT1A | TSHR 2845/4885 |
| US-20260028231-A1 | SURFACE-MODIFIED NANODIAMONDS AND METHOD FOR PRODUCING SURFACE-MODIFIED NANO CARBON PARTICLES | NOX1, NOXO1, HAO2 | TSHR 2424/4885 |
| US-12534374-B2 | Surface-modified nanodiamond and method for producing surface-modified nanodiamond | SGMS1, SGMS2, PHOSPHO1 | TSHR 2870/4885 |
| US-20030059710-A1 | Monomer having electron-withdrawing group and process for preparing the same | RFC3, RFC2, MAPRE1 | TSHR 783/4885 |
| US-12545753-B2 | Curable composition | SCO2, CBR1, COL1A1 | TSHR 4075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.